Optimizing Drug Loading in Amorphous Solid Dispersions: Maximizing Bioavailability While Minimizing Pill Burden

Amorphous solid dispersions (ASDs) have revolutionized drug delivery by enhancing the bioavailability of poorly soluble drugs. However, formulators often assume that higher drug loading in ASDs will automatically reduce pill burden by minimizing excipient content. This approach overlooks a critical factor: increasing the drug-to-polymer ratio can significantly reduce the fraction of drug absorbed, ultimately leading to higher doses and offsetting any initial benefits of reduced formulation mass.

Dave Miller, AustinPx CSO (Chief Scientific Officer), will challenge this common misconception and provide a framework for optimizing ASD formulations to achieve both maximum bioavailability and minimal pill burden. Through scientific insights and real-world examples, the speaker will provide formulation scientists and drug developers with the knowledge needed to make data-driven decisions when designing ASDs.